Biomedical Engineering Reference
In-Depth Information
evaluation of gastrointestinal stromal tumor patients treated with
sunitinib malate after imatinib failure.
Clin Cancer Res
2009; 15(18):
5902-5909.
106. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar
J,
Early prediction of response to sunitinib after imatinib failure
by 18F-fluorodeoxyglucose positron emission tomography in patients
with gastrointestinal stromal tumor.
et al.
J Clin Oncol
2009; 27(3): 439-
445.
107. Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD,
et al.
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors
harboring KITAY502-3ins mutation: an in vitro mutagenesis screen
for drug resistance.
Clin Cancer Res
2009; 15(22): 6862-6870. PMCID:
2783687.
108. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction
with an angiogenesis inhibitor sunitinib: systematic review and meta-
analysis.
2009; 48(1): 9-17.
109. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M,
Acta Oncol
A
preeclampsia-like syndrome characterized by reversible hypertension
and proteinuria induced by the multitargeted kinase inhibitors
sunitinib and sorafenib.
et al.
2008; 100(4): 282-284.
110. Grossman M, Premaratne E, Desai J, Davis I. Thyrotoxicosis during
sunitinib treatment for renal cell cancer.
J Natl Cancer Inst
Clin Endocrinol
2008; 69(4):
669-672.
111. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W,
A
missense mutation in KIT kinase domain 1 correlates with imatinib
resistance in gastrointestinal stromal tumors.
et al.
Cancer Res
2004; 64(17):
5913-5919.
112. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N,
et
al.
Mechanisms of resistance to imatinib mesylate in gastrointestinal
stromal tumors and activity of the PKC412 inhibitor against imatinib-
resistant mutants.
2005; 128(2): 270-279.
113. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts
PJ,
Gastroenterology
Molecular correlates of imatinib resistance in gastrointestinal
stromal tumors.
et al.
2006; 24(29): 4764-4774.
114. Campbell NP, Wroblewski, K., Maki, RG, D'Adamo DR, Chow WA, Gandara
DR, Antonescu C, Stadler WM, Vokes EE, Kindler HL. Final results of the
University of Chicago phase II consortium trial of sorafenib (SOR) in
patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES)
gastrointestinal stromal tumor (GIST) (abstract). ASCO GI Cancers
Symposium. 2011.
J Clin Oncol
